Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 141 to 150 of 242 total matches.
Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022 (Issue 1641)
to have an inadequate antibody
response to COVID-19 vaccination and severe
breakthrough infection requiring ...
The FDA has issued an Emergency Use Authorization
(EUA) for the investigational long-acting monoclonal
antibodies tixagevimab and cilgavimab (Evusheld –
AstraZeneca) to be administered concomitantly by IM
injection for pre-exposure prophylaxis of COVID-19 in
persons ≥12 years old who weigh ≥40 kg and have
either a history of severe allergy that prevents their
vaccination against COVID-19 or moderate or severe
immune compromise (see Table 1). They are the first
drugs to be authorized by the FDA for this indication.
Two other pairs of antibodies, bamlanivimab plus
etesevimab...
An EUA for Anakinra (Kineret) for COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
levels
(14% vs 12%). Neutropenia, serious infections, and
hypersensitivity reactions, including ...
The recombinant interleukin-1 (IL-1) receptor
antagonist anakinra (Kineret – Sobi) has been
granted an FDA Emergency Use Authorization
(EUA) for treatment of hospitalized adults with
confirmed COVID-19 pneumonia who require low- or
high-flow supplemental oxygen, are at risk of
progressing to severe respiratory failure, and are
likely to have elevated plasma levels of soluble
urokinase plasminogen activator receptor (suPAR).
Anakinra has been available in the US for years; it
is FDA-approved for multiple indications, including
rheumatoid arthritis. Assays for suPAR are...
Fitusiran (Qfitlia) for Hemophilia A and B
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025 (Issue 1732)
infections and nasopharyngitis. Serious thrombotic events and
gall bladder disease can occur in patients ...
Fitusiran (Qfitlia – Sanofi), a subcutaneously injected,
antithrombin-directed, small interfering ribonucleic
acid (siRNA), has been approved by the FDA for routine
prophylaxis to prevent or reduce the frequency of
bleeding episodes in patients ≥12 years old who have
hemophilia A with or without factor VIII inhibitors or
hemophilia B with or without factor IX inhibitors. It
is the first antithrombin-lowering therapy to become
available in the US for treatment of hemophilia.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):110-1 doi:10.58347/tml.2025.1732c | Show Introduction Hide Introduction
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
the other S1P receptor modulators, ozanimod may increase
the risk of infection and cause bradycardia and AV ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
An EUA for Bebtelovimab for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
confirmatory testing for SARS-CoV-2 infection within
the previous 3 days. BLAZE-4 was completed before ...
The investigational monoclonal antibody
bebtelovimab (LY-CoV1404 – Lilly) has been granted
an FDA Emergency Use Authorization (EUA) for IV
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death, and for whom alternative
treatment options are unavailable or inappropriate.
Bebtelovimab is active against the Omicron variant of
SARS-CoV-2; sotrovimab (VIR-7831) is the only other
monoclonal antibody currently available for treatment
of COVID-19 that is active...
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022 (Issue 1660)
, nasopharyngitis,
headache, urinary tract infection, and pyrexia.
Nonmelanoma skin cancers have occurred with use ...
The 1.5% cream formulation of the Janus kinase
(JAK) inhibitor ruxolitinib (Opzelura – Incyte) has
been approved by the FDA for topical treatment of
nonsegmental vitiligo (NSV) in patients ≥12 years old.
Opzelura is the first product to be approved by the
FDA for this indication. It was previously approved for
treatment of atopic dermatitis.
Relyvrio for ALS
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
: Diarrhea, abdominal pain, nausea, and upper
respiratory tract infection have been reported with use ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose
combination of sodium phenylbutyrate and
taurursodiol, for treatment of amyotrophic lateral
sclerosis (ALS). Sodium phenylbutyrate (Buphenyl,
and others) has been available by prescription
for years for treatment of urea cycle disorders.
Taurursodiol (tauroursodeoxycholic acid), a derivative
of ursodiol, is an over-the-counter bile acid
supplement claimed to have neuroprotective
benefits. Relyvrio is the third drug to be approved
in the US for treatment of ALS; riluzole (Rilutek, and
others) and edaravone (Radicava, Radicava...
Etrasimod (Velsipity) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
, dizziness, and arthralgia have been reported. Severe infections, transient reductions in heart rate ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be approved
in the US for this indication; ozanimod (Zeposia) was
the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9 doi:10.58347/tml.2023.1690b | Show Introduction Hide Introduction
Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
— Adverse effects reported
with use of Eohilia in the two trials include
respiratory tract infection ...
Eohilia (Takeda), an oral suspension formulation of
the corticosteroid budesonide, has been approved
by the FDA for treatment of eosinophilic esophagitis
(EoE) in patients ≥11 years old. It is the first oral
drug to be approved in the US for this indication. The
subcutaneously injected interleukin (IL)-4 receptor
antagonist dupilumab (Dupixent) is approved
for treatment of EoE in patients ≥1 year old who
weigh ≥15 kg.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):93-5 doi:10.58347/tml.2024.1704c | Show Introduction Hide Introduction
Ensifentrine (Ohtuvayre) for COPD
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
an inhaled corticosteroid (ICS).
Adverse Effects: Back pain, hypertension, urinary tract
infection ...
The FDA has approved ensifentrine (Ohtuvayre –
Verona), an inhaled phosphodiesterase (PDE) 3 and
4 inhibitor, for maintenance treatment of chronic
obstructive pulmonary disease (COPD) in adults.
It is the first dual inhibitor of PDE3 and PDE4 to be
approved by the FDA, and the first inhaled drug
with a new mechanism of action to be approved for
treatment of COPD in more than 20 years.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):131-3 doi:10.58347/tml.2024.1709b | Show Introduction Hide Introduction